Key Takeaways
- Guidance raised, margin expansion intact: Operating EBITDA margin guidance raised for the third straight year to 27%-29%, backed by a 90 bps expansion to 25.3% this quarter and a clear path from mix shift and ophthal upside.
- Domestic business is the engine: India formulations grew +11% (IQVIA +13% vs industry 7%), with chronic at +16% and ophthal at +22%; the company has sustained a 3-4 ppt premium to market growth for 4-5 years.
- CDMO poised for a step-change: Current quarterly run-rate of ~₹110 crore is expected to jump to ~₹150 crore as four to five marquee projects commercialize by year-end, targeting 12-14% growth thereafter.
- Ophthal perpetual license is a margin catalyst: When the license triggers in December 2026, gross margin on the ₹200 crore+ franchise shifts from ~20% to near-domestic levels, with most of that gain flowing to EBITDA.
- What to watch next quarter: Whether Azmarda hits the 140,000+ units/month target, CDMO project commercialization timelines hold, and the pace of the promised 30-50 bps gross margin improvement in FY26.
Domestic Formulations: The Growth Anchor
- Chronic leadership compounding: Chronic portfolio grew 18% vs IPM chronic at 10%, with flagship brands consistently outpacing their markets: Cilacar Plain at 19% vs 16% (holding ~60% share), Cilacar T at 37% vs 25%, Razel at 24% vs 14%, Nicardia at >20%.
- Acute portfolio holding its own: Acute grew 10%, supported by the Sporlac franchise which has doubled from ₹69 crore to ₹134 crore in three years and entered the top-300 brands.
- Brand depth transformed: 25 brands now above ₹20 crore (vs 8 four years ago), 6 above ₹100 crore, driven by field force productivity that nearly doubled from 4.6 lakh PCPM in FY21 to 8 lakh PCPM.
- Ophthal scaling fast: The segment grew 22% to ₹56 crore this quarter, with an annualized run rate close to ₹200 crore+; prescriber expansion and new launches are gaining traction.
- Azmarda gaining share: Q4 growth of 30% vs the category at 20%; management expects the Sacubitril Valsartan market to sustain mid-teens volume growth and targets a ₹100 crore franchise over 2-3 years.
- Sequential dip is seasonal, not structural: The QoQ decline in India revenue reflects March trade inventory rationalization, not demand or prescription weakness.
- Progressive portfolio dominance: 75% of the progressive portfolio is beating market growth significantly; non-progressive drag is limited to specific SKUs like Ranitidine Plain and Nicardia Plain where Nicardia XL is driving the franchise shift.
Chopra: "We are raising our operating margin guidance for the third year in row. EBITDA margins will be in the range of 27% to 29%. Once again, I will repeat, we are revising our operating EBITDA guidance for the third year in row."
CDMO: The Inflection Trade
- New projects are the story: Four to five marquee projects are in the pipeline: lozenges for Europe and North America, a Pan-India ORS project, throat sprays for cough/cold across multiple markets, and iodine-based formulations; all expected to commercialize by year-end.
- Run-rate jump quantified: The current ~₹110 crore quarterly run-rate is expected to become ~₹150 crore per quarter starting next financial year once these projects see daylight, with 12-14% growth thereafter.
- Anchor client strategy: The company aims to add at least one or two anchor clients every year, building on a base that has normalized after the FY23 inventory spike.
- FY25 recovery path: CDMO grew 18% in Q4 to ₹129 crore, driving the entire international growth; full-year CDMO was +3% after a strong H2 recovery from earlier destocking.
Chopra: "These are four or five big projects which we will be able to commercialize by the end of the year. And starting next financial year, our run rate that we assume with all these businesses is seeing the daylight which today is around INR110 crore every quarter should be around INR150 crore every quarter."
Ophthal: The Embedded Margin Call Option
- Perpetual license trigger in December 2026: At that point, JB becomes the full-fledged custodian of the trademarks, and the gross margin profile shifts from the current ~20% to a level much closer to the domestic gross margin profile.
- Revenue scale at trigger: The franchise is targeting close to ₹230 crore when the license triggers, up from the current ₹200 crore+ annualized run rate, growing at a mid-teen pace.
- EBITDA flow-through is high: A significant part of the gross margin uplift will flow through to EBITDA; management clarified this is not a function of productivity being impacted or more people being added, it is structural margin accretion.
- Current trajectory on track: The business is growing at 22% vs the market at 11-12%, with prescriber expansion and new launches contributing.
Khanna: "When the perpetual license triggers the gross margin profile changes significantly from the current conventional margin profile of closer to 20%, it will be much closer to our domestic gross margin profile. One can do the math and that's the significant upside we see kicking in, in our overall profitability."
International Formulations: Selective Growth, Margin Repair
- Russia and branded generics lead: International formulations grew 6% to ₹282 crore, backed by double-digit growth in Russia and branded generic exports; Russia remains a good story for both top line and profit margins.
- South Africa repositioned: A ₹120 crore cut from exiting the tender business improved profitability as the mix shifted to private market, now 65-70% vs 40% earlier.
- BGX reset and reload: 50% of the business was tender participation where competitive pricing was an issue; from FY27 onwards, growth is expected at 10% short-to-medium term and 12%+ medium-to-long term, supported by filing 8-10 progressive products every year across 40 countries in Sub-Saharan Africa, Latin America, Southeast Asia and the Middle East.
- Progressive portfolio going global: Gliptins, Glozins, heart failure products and eye drops are being filed for export markets, with commercialization starting early FY27; branded generic export growth is expected to move from ~10% to ~12% from FY27 onwards.
- API business rationalized: Third-party sales are range-bound as the diclofenac market has matured; the API is now directed to captive consumption to improve US ANDA margin profiles.
Margins & Capital Allocation
- Margin walk in Q4: Gross margin expanded 90 bps YoY to 66.1%, driven by favorable product/business mix and cost optimization; other expenditure as a percentage of sales reduced 80 bps to 23.7%, delivering a 90 bps EBITDA margin expansion to 25.3%.
- FY25 full-year margin resilience: Gross profit at 66.4% expanded 30 bps despite the in-licensed ophthalmology portfolio drag; ex-ophthalmology, the expansion was 130 bps.
- FY26 gross margin path: 30-50 bps improvement expected, supported by cost initiatives and mix as chronic grows faster than acute.
- Cash generation best-in-class: Operating cash flows at ₹903 crore vs ₹801 crore; operating cash flow to EBITDA at 83%, among the highest in the pharma industry.
- Balance sheet transformed: Net cash position of ₹689 crore vs ₹107 crore a year ago; finance costs declined from ₹9 crore to ₹1 crore due to gross debt reduction.
- Return ratios climbing: ROC improved to 32% from 27%; ROE at 19.2%.
- Capex and depreciation outlook: ₹100 crore capex each year for the next two years, with maintenance at 65-70% and growth at 25-30%; depreciation will increase only 4-5%.
- Dividend policy steady: Payout ratio to continue at 35%; total dividend for FY25 at ₹15.50 per share including ₹8.50 interim and ₹7 final.
- In-licensing appetite defined: Willingness to go up to 1.5x EBITDA for buying out companies or brands, targeting quality assets in growth markets with a 7-8 year payback period.
Regulatory & Risk
- Rantac status stable: No ban on Rantac; the government has issued instructions on quality monitoring, which the company has been doing for years; the molecule has been relaunched in some markets. Management declined to comment on hypothetical withdrawal scenarios, noting the product is part of the mass division and not a priority product.
- Plant compliance spotless: Facilities continue to be audited by the US FDA and other regulatory authorities with no 483s and no observations.
Chopra: "Our plants also continue to get audited by US FDA, by other regulatory authorities and our people at the plants also have done a fantastic job in terms of facing those audits and not only no 483, no observations. That is what we can boast in terms of what we have delivered as a company."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating EBITDA margin | 27%-29% range (ex-ESOP) | FY26 (guidance raised for third straight year) |
| CDMO quarterly run-rate | ~₹150 crore (from ~₹110 crore currently) | Starting next financial year (FY27) |
| CDMO growth rate | 12%-14% | Ongoing from FY27 |
| Gross margin improvement | 30-50 bps expansion | FY26 |
| Azmarda monthly run-rate | 140,000+ units | By end of H1 FY26 (next quarter) |
| Azmarda franchise size | ₹100 crore | Over next 2-3 years |
| Ophthal revenue at license trigger | Close to ₹230 crore | December 2026 (perpetual license trigger) |
| Branded generic export growth | ~12% (from ~10% currently) | From FY27 onwards |
| BGX growth | 10% short-to-medium term; 12%+ medium-to-long term | From FY27 onwards |
| Capex | ₹100 crore per year (65-70% maintenance, 25-30% growth) | Next two years |
| Depreciation increase | 4%-5% | FY26 |
| Other income (treasury) | ₹65-70 crore | FY26 |
| Dividend payout ratio | ~35% | Ongoing |
| Anchor client additions (CDMO) | At least 1-2 per year | Ongoing |
| Productivity improvement | 12%-14% increase | Over next 2-3 years |
| India vs market growth premium | 3-4 percentage points above IPM | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹949 crore, +10% YoY |
| Operating EBITDA | ₹240 crore, +15% YoY |
| Operating EBITDA margin | 25.3%, +90 bps YoY |
| Net profit | ₹146 crore, +15% YoY |
| Gross margin | 66.1%, +90 bps YoY |
| Domestic business revenue | ₹519 crore, +11% YoY |
| Domestic business IQVIA growth | 13% YoY vs industry 7% |
| International business revenue | ₹430 crore, +9% YoY |
| CDMO revenue | ₹129 crore, +18% YoY |
| International formulations revenue | ₹282 crore, +6% YoY |
| Ophthal business revenue | ₹56 crore, +22% YoY |
| Chronic portfolio IQVIA growth | 16% YoY |
| Acute portfolio IQVIA growth | 10% YoY |
| Field force productivity | 8 lakh PCPM vs 4.6 lakh in FY21 |
| Net cash | ₹689 crore as of 31 March 2025 vs ₹107 crore prior year |
| ROC | 32% vs 27% in FY24 |
| ROE | 19.2% |
| Operating cash flow to operating EBITDA | 83% |
| FY26 operating EBITDA margin guidance | 27% to 29%, revised upward for third consecutive year |
| FY26 gross margin improvement guidance | 30 to 50 bps improvement |
| FY26 other income guidance | ₹65 to ₹70 crore as treasury income |
| FY26-27 capex guidance | ~₹100 crore per year |
| Dividend per share | ₹15.50 total for FY25, including ₹7 final and ₹8.50 interim |